MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) is set to release its 2021 fourth quarter and full year financial results on February 24, 2022, at 5:00 p.m. Eastern Time. The call will feature CEO Michael Castagna and CFO Steven Binder, discussing key financial outcomes and corporate updates. MannKind focuses on inhaled therapeutic products, notably the FDA-approved Afrezza^®, an ultra rapid-acting mealtime insulin available nationwide in the U.S. and Brazil through partner Biomm SA.

Positive

• MannKind is commercializing Afrezza, the only inhaled ultra rapid-acting mealtime insulin in the U.S.
• Afrezza is also available in Brazil, expanding market reach.

Negative

• None.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00 p.m. (Eastern Time) on Thursday, February 24, 2022.

Presenting from the Company will be its Chief Executive Officer Michael Castagna and Chief Financial Officer Steven Binder.

Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at mannkindcorp.com under Events & Presentations.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

FAQ

When will MannKind Corporation release its financial results?

MannKind Corporation will release its 2021 fourth quarter and full year financial results on February 24, 2022, at 5:00 p.m. Eastern Time.

Who will discuss MannKind's financial results during the conference call?

CEO Michael Castagna and CFO Steven Binder will present during MannKind's conference call.

What is Afrezza and why is it significant for MannKind?

Afrezza is the only inhaled ultra rapid-acting mealtime insulin approved by the FDA, marking a unique offering in MannKind's product portfolio.

Where can I listen to MannKind's conference call?

The conference call can be accessed live on the Investors page of MannKind's website at mannkindcorp.com.